BRNS (Barinthus Biotherapeutics) OCF Margin %: 0.00% (As of Mar. 2026)


BRNS Barinthus Biotherapeutics PLC BRNS
52 GF Score
Price $0.70
GF Value $1.12
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Barinthus Biotherapeutics OCF Margin %?

Barinthus Biotherapeutics BRNS +2.94% 52 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates BRNS with a GF Score™ of 52/100 and a GF Value™ of $1.12 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 958 Biotechnology companies, Barinthus Biotherapeutics ranks worse than 104384.03% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Barinthus Biotherapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-3.37 Mil. Barinthus Biotherapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Barinthus Biotherapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Barinthus Biotherapeutics's current OCF Yield % is -127.45%.

The historical rank and industry rank for Barinthus Biotherapeutics's OCF Margin % or its related term are showing as below:


During the past 7 years, the highest OCF Margin % of Barinthus Biotherapeutics was -32.28%. The lowest was -12157.84%. And the median was -228.75%.

BRNS's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Barinthus Biotherapeutics OCF Margin % Related Terms

Barinthus Biotherapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Barinthus Biotherapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Barinthus Biotherapeutics OCF Margin % Chart

Barinthus Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial -12,157.84 -32.28 -6,349.75 -193.33 0.00

Barinthus Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BRNS
52GF Score
Barinthus Biotherapeutics PLC BRNS
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Barinthus Biotherapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Barinthus Biotherapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-47.979/0
= %

Barinthus Biotherapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-3.366/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Barinthus Biotherapeutics (BRNS) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Barinthus Biotherapeutics and its competitors. According to the industry distribution chart, Barinthus Biotherapeutics ranks #999999 out of 958 companies in the Biotechnology industry.
Is Barinthus Biotherapeutics' OCF Margin % too high?
Barinthus Biotherapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Barinthus Biotherapeutics ranks #999999 out of 958 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Barinthus Biotherapeutics has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' OCF Margin % compare to KYNB and SER?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #999999 out of 958 companies for OCF Margin %. This places Barinthus Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Barinthus Biotherapeutics and its competitors. Barinthus Biotherapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Barinthus Biotherapeutics (BRNS) is currently considered Possible Value Trap. The stock's GF Value™ is $1.12, compared to a current price of $0.70 — trading 37.5% below its estimated fair value. The current OCF Margin % is 0.00%. Barinthus Biotherapeutics' overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Barinthus Biotherapeutics (BRNS), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Barinthus Biotherapeutics (BRNS) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of $0.70 is trading 37.5% below its estimated GF Value™ of $1.12. GuruFocus considers Barinthus Biotherapeutics to be Possible Value Trap.

Key valuation signals for BRNS:

  • OCF Margin %: 0.00%
  • GF Value™: $1.12 vs. price of $0.70 (37.5% below fair value)
  • GF Score™: 52/100 with 1 warning sign

No single metric tells the full story. See the BRNS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Barinthus Biotherapeutics Business Description

Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
52GF Score

Get the complete analysis for BRNS

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70
Price
$1.12
GF Value